Pfizer to sell off Remicade biosim in EU to win Hospira deal nod; Sanofi prices Toujeo on par with Lantus in U.K.;

> Pfizer ($PFE) won E.U. approval for its $16 billion Hospira ($HSP) purchase after the company agreed to sell European rights to its biosimilar version of Remicade (infliximab). Report

> Sanofi ($SNY) priced Toujeo, its new longer-acting version of Lantus, on par with the older med in the U.K. in hopes of grabbing market share to withstand generic rivals. Report

> Over the long term, birth control pills actually protect against uterine cancer, contrary to fears that they could cause the disease, a new study found. Report

> AB Science has been studying its drug candidate masitinib in a wide swath of diseases, though it has only won approval to market the drug to treat cancer in dogs. Report

And Finally... A new analysis of anti-dementia drugs such as Eisai's Aricept found that the cholinesterase inhibitors can cause harmful weight loss. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.